title: Administration of atosiban in patients with endometriosis undergoing frozen-thawed embryo transfer: a prospective, randomized study.
abstract: OBJECTIVE
  To examine the effects of atosiban, given before transfer of frozen-thawed embryo to women with endometriosis (EMs).
  
  
  METHODS
  A randomized, controlled clinical trial.
  
  
  METHODS
  University hospital and IVF center.
  
  
  METHODS
  One hundred twenty women with endometriosis undergoing frozen-thawed embryo transfer were randomly allocated into the atosiban treatment and the control groups. Another 120 women with infertility due to tubal factor were enrolled into a tubal factor group, to compare serum oxytocin (OT) and prostaglandin (PG)F2α levels and uterine contractions with the endometriosis group.
  
  
  METHODS
  In the endometriosis treatment group, a single bolus (6.75 mg, 0.9 mL per vial) of atosiban was administrated before ET.
  
  
  METHODS
  Implantation rate and pregnancy rate.
  
  
  RESULTS
  Serum OT level (1.89 ± 0.33 vs. 1.66 ± 0.32 ng/L), PGF2α (2.83 ± 0.34 vs. 2.36 ± 0.35 ng/L) level, and uterine contractions (2.5 ± 1.2 vs. 1.8 ± 1.0 waves per minute) in the endometriosis group were all significantly higher than in the tubal factor group. The clinical pregnancy rate per cycle and implantation rate per transfer were 58.3% and 41.0%, respectively, in the atosiban treatment group, significantly higher than in the control group (38.3% and 23.4%, respectively).
  
  
  CONCLUSIONS
  Women with endometriosis showed higher serum OT level, PGF2α level, and uterine contractions. Atosiban treatment before ET in endometriosis is effective in the priming of the uterus, suitable for embryo implantation. This is the first study to evaluate the effect of atosiban treatment in patients with endometriosis.
  
  
  BACKGROUND
  ChiCTR-IOQ-14005715.
authors.affiliation: Department of Obstetrics and Gynecology, Reproductive Medicine Center, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.
authors.forename: Ye
authors.initials: Y
authors.lastname: He
authors.affiliation: Department of Obstetrics and Gynecology, Reproductive Medicine Center, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.
authors.forename: Huan
authors.initials: H
authors.lastname: Wu
authors.affiliation: Department of Obstetrics and Gynecology, Reproductive Medicine Center, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.
authors.forename: Xiaojin
authors.initials: X
authors.lastname: He
authors.affiliation: Department of Obstetrics and Gynecology, Reproductive Medicine Center, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.
authors.forename: Qiong
authors.initials: Q
authors.lastname: Xing
authors.affiliation: Department of Obstetrics and Gynecology, Reproductive Medicine Center, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.
authors.forename: Ping
authors.initials: P
authors.lastname: Zhou
authors.affiliation: Department of Obstetrics and Gynecology, Reproductive Medicine Center, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.
authors.forename: Yunxia
authors.initials: Y
authors.lastname: Cao
authors.affiliation: Department of Obstetrics and Gynecology, Reproductive Medicine Center, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China. Electronic address: weizhaolian_1@126.com.
authors.forename: Zhaolian
authors.initials: Z
authors.lastname: Wei
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D002681:China; D015925:Cryopreservation; D015237:Dinoprost / Q000097:blood; D004334:Drug Administration Schedule; D010064:Embryo Implantation / Q000187:drug effects; D004624:Embryo Transfer / Q000009:adverse effects; D004715:Endometriosis / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005298:Fertility; D005307:Fertilization in Vitro / Q000009:adverse effects; D006727:Hormone Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D006785:Hospitals, University; D006801:Humans; D007247:Infertility, Female / Q000097:blood / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D008875:Middle Aged; D010121:Oxytocin / Q000097:blood; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014590:Uterine Contraction / Q000187:drug effects; D014668:Vasotocin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D055815:Young Adult
chemical_list: D015415:Biomarkers; D006727:Hormone Antagonists; C047046:atosiban; D010121:Oxytocin; D015237:Dinoprost; D014668:Vasotocin
keywords: Atosiban; clinical pregnancy rate; endometriosis; oxytocin; uterine contractility